MX2021012423A - Métodos y composiciones para degradación de proteínas específicas. - Google Patents

Métodos y composiciones para degradación de proteínas específicas.

Info

Publication number
MX2021012423A
MX2021012423A MX2021012423A MX2021012423A MX2021012423A MX 2021012423 A MX2021012423 A MX 2021012423A MX 2021012423 A MX2021012423 A MX 2021012423A MX 2021012423 A MX2021012423 A MX 2021012423A MX 2021012423 A MX2021012423 A MX 2021012423A
Authority
MX
Mexico
Prior art keywords
compositions
methods
protein degradation
targeted protein
targeted
Prior art date
Application number
MX2021012423A
Other languages
English (en)
Inventor
Weiwen Ying
Long Ye
Kevin Foley
Original Assignee
Ranok Therapeutics Hangzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranok Therapeutics Hangzhou Co Ltd filed Critical Ranok Therapeutics Hangzhou Co Ltd
Publication of MX2021012423A publication Critical patent/MX2021012423A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Se proporcionan compuestos con la Fórmula I: (Ver fórmula I), y sales y composiciones de estos aceptables desde un punto de vista farmacéutico, que son útiles para tratar cánceres y afecciones relacionadas.
MX2021012423A 2019-04-09 2020-04-08 Métodos y composiciones para degradación de proteínas específicas. MX2021012423A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2019/081919 WO2020206608A1 (en) 2019-04-09 2019-04-09 Methods and compositions for targeted protein degradation
PCT/CN2020/083647 WO2020207395A1 (en) 2019-04-09 2020-04-08 Methods and compositions for targeted protein degradation

Publications (1)

Publication Number Publication Date
MX2021012423A true MX2021012423A (es) 2022-01-19

Family

ID=72750919

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012423A MX2021012423A (es) 2019-04-09 2020-04-08 Métodos y composiciones para degradación de proteínas específicas.

Country Status (12)

Country Link
US (2) US20220162228A1 (es)
EP (2) EP3952914A4 (es)
JP (2) JP2022528568A (es)
KR (1) KR20220007055A (es)
CN (1) CN113924123A (es)
AU (2) AU2020256814A1 (es)
BR (1) BR112021020285A2 (es)
CA (2) CA3136372A1 (es)
IL (1) IL287082A (es)
MX (1) MX2021012423A (es)
SG (1) SG11202111193UA (es)
WO (3) WO2020206608A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230414723A1 (en) * 2020-10-26 2023-12-28 Trustees Of Tufts College Enhanced hyt-induced protein degradation using lipid nanoparticle delivery
CN112979657A (zh) * 2021-02-03 2021-06-18 福建医科大学 一种靶向降解Hsp90蛋白的化合物及其制备方法与应用
CN115232030A (zh) * 2021-04-23 2022-10-25 中国医学科学院药物研究所 芳基脲类化合物及其制法和药物用途
WO2023283130A1 (en) 2021-07-04 2023-01-12 Newave Pharmaceutical Inc. Isoquinoline derivatives as mutant egfr modulators and uses thereof
WO2023061440A1 (en) * 2021-10-14 2023-04-20 Cullgen (Shanghai), Inc. Modified proteins and protein degraders
CN114907386B (zh) * 2022-03-11 2023-03-31 山东大学 一种hemtac小分子降解剂及其应用
WO2024037527A1 (en) * 2022-08-16 2024-02-22 Beijing Neox Biotech Limited Btk degrading compounds
WO2024075051A1 (en) 2022-10-07 2024-04-11 Pfizer Inc. Hsd17b13 inhibitors and/or degraders
WO2024127297A1 (en) 2022-12-16 2024-06-20 Pfizer Inc. 3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2621141T3 (es) 2008-11-28 2017-07-03 Novartis Ag Combinación farmacéutica que comprende un inhibidor de Hsp 90 y un inhibidor de mTOR
US9249161B2 (en) * 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2802608A4 (en) * 2012-01-12 2015-08-05 Univ Yale COMPOUNDS AND METHODS FOR ENHANCED DEGRADATION OF TARGET PROTEINS AND OTHER POLYPEPTIDES BY E3 UBIQUITIN LIGASE
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
US20160009725A1 (en) * 2013-02-22 2016-01-14 Bayer Pharma Aktiengesellschaft Pyrrolo- and pyrazolo-triazolodiazepines as bet-protein inhibitors for treating hyperproliferative diseases
CN105164135A (zh) * 2013-02-22 2015-12-16 拜耳医药股份有限公司 4-取代的吡咯并二氮杂卓和吡唑并二氮杂卓
AU2014229240B2 (en) 2013-03-15 2017-06-15 Novartis Ag Biomarkers of tumor pharmacodynamic response
AU2014318826B2 (en) * 2013-09-10 2019-10-10 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
EP3131586A4 (en) * 2014-03-18 2017-10-25 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
US20170136085A1 (en) * 2014-05-29 2017-05-18 Synta Pharmaceuticals Corp. Targeted therapeutics
JP6815318B2 (ja) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
PL3458101T3 (pl) * 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
GB2554071A (en) * 2016-09-14 2018-03-28 Univ Dundee Small molecules
AU2018215212B2 (en) 2017-01-31 2022-06-02 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
CN108129484B (zh) * 2017-12-19 2021-04-27 郭守东 杂芳环衍生物
CN108084193A (zh) * 2017-12-19 2018-05-29 郭守东 一种brd4蛋白抑制剂

Also Published As

Publication number Publication date
WO2020207395A1 (en) 2020-10-15
EP3953359A4 (en) 2023-07-19
SG11202111193UA (en) 2021-11-29
JP7512306B2 (ja) 2024-07-08
US20220168427A1 (en) 2022-06-02
EP3952914A4 (en) 2023-05-10
CN113939516A (zh) 2022-01-14
AU2020256600A1 (en) 2021-12-02
EP3952914A1 (en) 2022-02-16
EP3953359A1 (en) 2022-02-16
WO2020206608A1 (en) 2020-10-15
JP2022528767A (ja) 2022-06-15
CN113924123A (zh) 2022-01-11
US20220162228A1 (en) 2022-05-26
IL287082A (en) 2021-12-01
KR20220007055A (ko) 2022-01-18
CA3136370A1 (en) 2020-10-15
JP2022528568A (ja) 2022-06-14
WO2020207396A1 (en) 2020-10-15
BR112021020285A2 (pt) 2021-12-14
CA3136372A1 (en) 2020-10-15
AU2020256814A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
MX2021012423A (es) Métodos y composiciones para degradación de proteínas específicas.
MX2023010806A (es) 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas.
MX2023004373A (es) Metodos y composiciones para la degradacion dirigida de proteinas.
MX2023009185A (es) Compuestos de benzamida.
PH12021500014A1 (en) Fused ring compounds
CR20220258A (es) Inhibidores de kras g12c
MX2022010952A (es) Compuestos para la degradacion dirigida de brd9.
MX2020001235A (es) Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
EA202193015A1 (ru) Ингибиторы cdk
MX2021011606A (es) Compuestos dirigidos a prmt5.
MX2021010870A (es) Bloqueadores de canales ionicos cargados y metodos de uso.
MX2022005335A (es) Bloqueadores de canales ionicos cargados y metodos de uso.
MX2022000310A (es) Inhibidores de proteina bcl-2.
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
MX2021007247A (es) Derivados de rapamicina.
PH12020551343A1 (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
MX2021007738A (es) Derivados de (piridin-2-il)amina como inhibidores de tgf-beta r1 (alk5) para el tratamiento de cancer.
MX2022002446A (es) Compuestos de pirrolopirimidina inhibidores de perk.
MX2022002443A (es) Compuestos inhibidores de perk.
MX2022007474A (es) Compuestos macrociclicos.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
PH12021550323A1 (en) Dendrimer formulations